Global week ahead: Is Novo Nordisk past 'peak uncertainty'?

Novo Nordisk is navigating significant headwinds ahead of its Q3 earnings, including declining sales, profit pressure, job cuts, and intense competition in the obesity drug market, compounded by U.S. presidential pressure on drug pricing. Analyst sentiment is divided, with some citing "peak uncertainty" but warranting a premium valuation, while others express concerns over competitive pricing and unreflected restructuring costs. Despite a recent boardroom shake-up and new CEO, the company remains strategically active, recently making a $9 billion bid for Metsera and a $5.2 billion offer for Akero Therapeutics to bolster its obesity and diabetes treatment portfolio.

Analysis

Novo Nordisk (NVO) faces significant headwinds ahead of its Q3 earnings, including a sharp decline in sales, profit pressure, and recent job cuts. The company's share price has been under pressure since the start of the year, reflecting operational challenges and intense competition in the obesity drug market. U.S. President Trump's October 17 statement on "much lower" Ozempic pricing further exacerbates revenue concerns.

Analyst sentiment is divided; Berenberg cites "peak uncertainty" but maintains a positive outlook due to NVO's superior growth and R&D returns. Conversely, Jefferies downgraded the stock to underperform, citing competitive and pricing pressures, while UBS highlighted concerns over the 8 billion DKK ($1.23 billion) restructuring cost and NVO's limited U.S. consumer experience. This is compounded by recent governance instability, including the shock resignation of the chair and six directors, leading to an upcoming EGM on November 14.

Despite internal turmoil and a new CEO, Novo Nordisk remains strategically active, pursuing significant M&A to bolster long-term growth. The company recently made a $9 billion bid for biotech group Metsera and offered $5.2 billion for Akero Therapeutics. These acquisitions align with NVO's stated strategy to treat more people with obesity and diabetes, signaling a proactive approach to market expansion amidst current pressures.

Key Decisions for Investors

• Investors should closely monitor Novo Nordisk's Q3 earnings report for clarity on sales declines, profit margins, and the impact of the 8 billion DKK restructuring cost.
• Evaluate the implications of the upcoming EGM and new board appointments on future governance stability and strategic direction, especially concerning U.S. market penetration and pricing negotiations.
• Consider the long-term strategic value of the Metsera and Akero Therapeutics acquisitions, weighing their potential to drive future growth against immediate operational headwinds and competitive pressures.